GlassScriptPhysician profile
Shannon Williamson Cribb
NPI 1285142216
$4,288.70
in general payments reported to CMS, 2019-2025
19 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $375 · 2023: $583 · 2024: $1,714 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,789 · Travel and Lodging: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,788.64 |
| Travel and Lodging | $552.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,337.85 | 2021-2024 | Cardiomems, Amplatzer Amulet, Amplatzer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $676.45 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $522.22 | 2021-2025 | Watchman Access System, Watchman Flx, Versacross Steerable Access Solution |
| Edwards Lifesciences Corporation | $266.89 | 2023-2025 | Sapien 3 Ultra Resilia, Hemosphere |
| Amgen INC. | $233.87 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $147.37 | 2023-2025 | |
| Heartflow, INC. | $144.94 | 2023 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $125.91 | 2021-2024 | Farxiga |
| Pfizer INC. | $122.69 | 2024-2025 | |
| Insmed, INC. | $115.70 | 2021 | |
| Scpharmaceuticals INC. | $105.35 | 2025 | |
| Cvrx, INC. | $97.95 | 2024-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $87.80 | 2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $83.83 | 2024-2025 | Wegovy |
| Medtronic, INC. | $66.76 | 2022-2025 | Cobalt Dr Mri Surescan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.22 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $45.62 | 2025 | Amvuttra, Onpattro |
| Irhythm Technologies, INC. | $39.38 | 2023-2024 | Zio Xt Patch |
| Teleflex LLC | $20.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Cribb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.